Publications by authors named "Erika Hitre"

Claim this Profile
T
Tumor Treating Fields With Gemcitabine and Nab-Paclitaxel for Locally Advanced Pancreatic Adenocarcinoma: Randomized, Open-Label, Pivotal Phase III PANOVA-3 Study.
Hani M Babiker, Vincent Picozzi, Sreenivasa R Chandana, Bohuslav Melichar, Anup Kasi, Erika Hitre

J Clin Oncol· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic relation of body mass index on extended aromatase inhibition treatment in postmenopausal patients with estrogen receptor positive breast cancer: A retrospective analysis of the SOLE trial.
Giacomo Biganzoli, Edoardo Isnaldi, François Richard, Giuseppe Marano, Patrizia Boracchi, Erika Hitre

Eur J Cancer· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bemarituzumab as first-line treatment for locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma: final analysis of the randomized phase 2 FIGHT trial.
Zev A Wainberg, Yoon-Koo Kang, Keun-Wook Lee, Shukui Qin, Kensei Yamaguchi, Erika Hitre

Gastric Cancer· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Increased Progression-Free Survival with Cabozantinib Versus Placebo in Patients with Radioiodine-Refractory Differentiated Thyroid Cancer Irrespective of Prior Vascular Endothelial Growth Factor Receptor-Targeted Therapy and Tumor Histology: A Subgroup Analysis of the COSMIC-311 Study.
Jaume Capdevila, Jolanta Krajewska, Jorge Hernando, Bruce Robinson, Steven I Sherman, Erika Hitre

Thyroid· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A plain language summary of the CheckMate 649 study: nivolumab in combination with chemotherapy compared to chemotherapy alone for untreated advanced or metastatic cancer of the stomach or esophagus.
Yelena Y Janjigian, Kohei Shitara, Markus Moehler, Marcelo Garrido, Pamela Salman, Erika Hitre

Future Oncol· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cabozantinib for previously treated radioiodine-refractory differentiated thyroid cancer: Updated results from the phase 3 COSMIC-311 trial.
Marcia S Brose, Bruce G Robinson, Steven I Sherman, Barbara Jarzab, Chia-Chi Lin, Erika Hitre

Cancer· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bemarituzumab in patients with FGFR2b-selected gastric or gastro-oesophageal junction adenocarcinoma (FIGHT): a randomised, double-blind, placebo-controlled, phase 2 study.
Zev A Wainberg, Peter C Enzinger, Yoon-Koo Kang, Shukui Qin, Kensei Yamaguchi, Erika Hitre

Lancet Oncol· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Corrigendum: High Neutrophil-to-Lymphocyte Ratio (NLR) and Systemic Immune-Inflammation Index (SII) are Markers of Longer Survival After Metastasectomy of Patients With Liver-Only Metastasis of Rectal Cancer.
Nándor Polk, Barna Budai, Erika Hitre, Attila Patócs, Tamás Mersich

Pathol Oncol Res· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
High Neutrophil-To-Lymphocyte Ratio (NLR) and Systemic Immune-Inflammation Index (SII) Are Markers of Longer Survival After Metastasectomy of Patients With Liver-Only Metastasis of Rectal Cancer.
Nándor Polk, Barna Budai, Erika Hitre, Attila Patócs, Tamás Mersich

Pathol Oncol Res· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cabozantinib for radioiodine-refractory differentiated thyroid cancer (COSMIC-311): a randomised, double-blind, placebo-controlled, phase 3 trial.
Marcia S Brose, Bruce Robinson, Steven I Sherman, Jolanta Krajewska, Chia-Chi Lin, Erika Hitre

Lancet Oncol· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial.
Yelena Y Janjigian, Kohei Shitara, Markus Moehler, Marcelo Garrido, Pamela Salman, Erika Hitre

Lancet· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Subcutaneous trastuzumab with pertuzumab and docetaxel in HER2-positive metastatic breast cancer: Final analysis of MetaPHER, a phase IIIb single-arm safety study.
Sherko Kuemmel, Carlo A Tondini, Jacinta Abraham, Zbigniew Nowecki, Bartosz Itrych, Erika Hitre

Breast Cancer Res Treat· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Genomic Aberrations and Late Recurrence in Postmenopausal Women with Hormone Receptor-positive Early Breast Cancer: Results from the SOLE Trial.
Elena Guerini-Rocco, Kathryn P Gray, Caterina Fumagalli, Marta Rita Reforgiato, Isabella Leone, Erika Hitre

Clin Cancer Res· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Metabolic Parameters as Predictors for Progression Free and Overall Survival of Patients with Metastatic Colorectal Cancer.
Zsuzsanna Nemeth, Wouter Wijker, Zsolt Lengyel, Erika Hitre, Katalin Borbely

Pathol Oncol Res· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomized Phase III Trial of Pegvorhyaluronidase Alfa With Nab-Paclitaxel Plus Gemcitabine for Patients With Hyaluronan-High Metastatic Pancreatic Adenocarcinoma.
Eric Van Cutsem, Margaret A Tempero, Darren Sigal, Do-Youn Oh, Nicola Fazio, Erika Hitre

J Clin Oncol· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Complex treatment of colorectal liver metastases Consensus Conference, Budapest, 5th April 2019].

Orv Hetil· September 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Final Analysis of the Prevention of Early Menopause Study (POEMS)/SWOG Intergroup S0230.
Halle C F Moore, Joseph M Unger, Kelly-Anne Phillips, Frances Boyle, Erika Hitre

J Natl Cancer Inst· February 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Predictive Value of Early Skin Rash in Cetuximab-Based Therapy of Advanced Biliary Tract Cancer.
Gábor Rubovszky, Barna Budai, Erna Ganofszky, Zsolt Horváth, Éva Juhos, Erika Hitre

Pathol Oncol Res· April 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial.
Marco Colleoni, Weixiu Luo, Per Karlsson, Jacquie Chirgwin, Stefan Aebi, Erika Hitre

Lancet Oncol· January 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Capecitabine in Combination with Docetaxel in First Line in HER2-Negative Metastatic Breast Cancer: an Observational Study.
Renáta Kószó, Dóra Sántha, László Büdi, József Erfán, Károly Győrfy, Erika Hitre

Pathol Oncol Res· July 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Docetaxel, cisplatin and 5-fluorouracil induction chemotherapy followed by chemoradiotherapy or chemoradiotherapy alone in stage III-IV unresectable head and neck cancer: Results of a randomized phase II study.
Zoltán Takácsi-Nagy, Erika Hitre, Éva Remenár, Ferenc Oberna, Csaba Polgár

Strahlenther Onkol· August 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy.
Halle C F Moore, Joseph M Unger, Kelly-Anne Phillips, Frances Boyle, Erika Hitre

N Engl J Med· March 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term outcomes with high-dose-rate brachytherapy for the management of base of tongue cancer.
Zoltán Takácsi-Nagy, Ferenc Oberna, Pál Koltai, Erika Hitre, Tibor Major

Brachytherapy· May 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A comparative analysis on the efficacy and safety of intaxel® and taxol® in advanced metastatic breast cancer.
Istvan Lang, Gabor Rubovszky, Zsolt Horvath, Erna Ganofszky, Eszter Szabo, Erika Hitre

J Clin Diagn Res· June 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98.
Sherene Loi, Nicolas Sirtaine, Fanny Piette, Roberto Salgado, Giuseppe Viale, Erika Hitre

J Clin Oncol· March 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis